Sepracor second-quarter revenues up at $264.4 million, six-month revenues rise to $550.1 million

By Lisa Kerner

Charlotte, N.C., July 21 - Sepracor Inc.'s consolidated revenues were $264.4 million for the three months ended June 30, up from $185.1 million reported for second-quarter 2005.

Net income for the quarter of $11.3 million, or $0.10 per diluted share, was up from the prior-year period's net loss of $7.4 million, or $0.07 per share.

For the six months ended June 30, Sepracor's consolidated revenues rose to $550.1 million from consolidated revenues of $304.1 million for the first half of 2005.

Net income for the first six months of 2006 was $21.5 million, or $0.19 per diluted share, up from a net loss of $30.0 million, or $0.29 per share, for the six months ended June 30.

As of June 30, Sepracor had about $944.5 million in cash and short- and long-term investments.

Company highlights for the second quarter include publication and presentation of Lunesta study results and the filing of an Investigational New Drug application for SEP-227162, a serotonin and norepinephrine reuptake inhibitor.

Sepracor Inc. is a research-based pharmaceutical company located in Marlborough, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.